You just read:

Daiichi Sankyo Presents Long-Term Phase 1 Results of Antibody Drug Conjugate DS-8201 in Patients with HER2-Expressing Breast, Gastric and Other Solid Cancers at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

News provided by

Daiichi Sankyo Company, Limited

01 Jun, 2018, 13:00 BST